Some megatrends in health care are occurring that deserve our attention. We already know that as much as one-third of the U.S ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, pu ...

"Our approach achieved remarkably high levels of gene correction," said Dr. György. "We observed average editing rates of 75% ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should not be taken lightly.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

The beginning of the new CPD cycle means it is time to prepare a new professional development plan (PDP) and sketch out areas ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...